Patents by Inventor Karin Lövgren-Bengtsson
Karin Lövgren-Bengtsson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240024468Abstract: Fraction A of Quil A can be used together with at least one other adjuvant for the preparation of an adjuvant composition, where the included adjuvant components act synergistically to enhance level of immune response and have synergistic immunomodulating activity on the co-administered antigens or immunogens. Other adjuvants can comprise saponins, naturally occurring, synthetic or semisynthetic saponin molecules; e.g. saponins and saponin fractions from Quil A, cell wall skeleton, block polymers, TDM, lipopeptides, LPS and LPS-derivatives, Lipid A from different bacterial species and derivatives thereof, e.g., monophosphoryl lipid A, CpG variants, CT and LT or fractions thereof.Type: ApplicationFiled: October 4, 2023Publication date: January 25, 2024Applicant: Novavax ABInventors: Bror MOREIN, Karin LÖVGREN BENGTSSON, Jill EKSTRÖM, Katarina RANLUND, Kefei HU
-
Publication number: 20220241408Abstract: Fraction A of Quil A can be used together with at least one other adjuvant for the preparation of an adjuvant composition, where the included adjuvant components act synergistically to enhance level of immune response and have synergistic immunomodulating activity on the co-administered antigens or immunogens. Other adjuvants can comprise saponins, naturally occurring, synthetic or semisynthetic saponin molecules; e.g. saponins and saponin fractions from Quil A, cell wall skeleton, block polymers, TDM, lipopeptides, LPS and LPS-derivatives, Lipid A from different bacterial species and derivatives thereof, e.g., monophosphoryl lipid A, CpG variants, CT and LT or fractions thereof.Type: ApplicationFiled: September 17, 2021Publication date: August 4, 2022Inventors: Bror MOREIN, Karin LÖVGREN BENGTSSON, Jill EKSTRÖM, Katarina RANLUND, Kefei HU
-
Publication number: 20200345840Abstract: Fraction A of Quil A can be used together with at least one other adjuvant for the preparation of an adjuvant composition, where the included adjuvant components act synergistically to enhance level of immune response and have synergistic immunomodulating activity on the co-administered antigens or immunogens. Other adjuvants can comprise saponins, naturally occurring, synthetic or semisynthetic saponin molecules; e.g. saponins and saponin fractions from Quil A, cell wall skeleton, block polymers, TDM, lipopeptides, LPS and LPS-derivatives, Lipid A from different bacterial species and derivatives thereof, e.g., monophosphoryl lipid A, CpG variants, CT and LT or fractions thereof.Type: ApplicationFiled: December 3, 2019Publication date: November 5, 2020Applicant: Novavax ABInventors: Bror MOREIN, Karin LÖVGREN BENGTSSON, Jill EKSTRÖM, Katarina RANLUND, Kefei HU
-
Patent number: 10729764Abstract: The invention relates to a composition comprising a mixture of at least two iscom complexes each complex comprising essentially one saponin fraction from Quillaja Saponaria Molina. The complexes may be iscom complexes or iscom matrix complexes. The invention also pertains to the use of such a mixture for the preparation of an immunomodulating pharmaceutical, and adjuvant, formulations for immunization, e.g. for production of monoclonal antibodies, and a vaccine. Kits of parts comprising at least two parts, wherein each part comprises one iscom complex or one iscom matrix complex according to the invention are also embraced.Type: GrantFiled: December 31, 2014Date of Patent: August 4, 2020Assignee: Novavax ABInventors: Bror Morein, Karin Lövgren Bengtsson
-
Publication number: 20200215189Abstract: The invention relates to a composition comprising a mixture of at least two iscom complexes each complex comprising essentially one saponin fraction from Quillaja saponaria Molina. The complexes may be iscom complexes or iscom matrix complexes. The invention also pertains to the use of such a mixture for the preparation of an immunomodulating pharmaceutical, and adjuvant, formulations for immunization, e.g. for production of monoclonal antibodies, and a vaccine. Kits of parts comprising at least two parts, wherein each part comprises one iscom complex or one iscom matrix complex according to the invention are also embraced.Type: ApplicationFiled: March 19, 2020Publication date: July 9, 2020Inventors: Bror MOREIN, Karin LÖVGREN-BENGTSSON
-
Patent number: 10485863Abstract: The present invention relates to a composition comprising at least one ISCOM complex and at least one ectodomain from at least one hemagglutinin (HA) domain and at least one ectodomain from at least one neuraminidase (NA) domain from one or more influenza virus, wherein the extodomains represent ectodomains isolated from the influenza virus. The invention also regards a kit. The composition may be used as an immune stimulating medicine, immune modulating pharmaceutical or a vaccine e.g. against influenza for vertebrates, e.g. birds and mammals.Type: GrantFiled: July 25, 2011Date of Patent: November 26, 2019Assignees: Novavax AB, Erasmus University Rotterdam Medical CenterInventors: Albertus D. M. E. Osterhaus, Bror Morein, Karin Lövgren Bengtsson
-
Publication number: 20180369368Abstract: Fraction A of Quil A can be used together with at least one other adjuvant for the preparation of an adjuvant composition, where the included adjuvant components act synergistically to enhance level of immune response and have synergistic immunomodulating activity on the co-administered antigens or immunogens. Other adjuvants can comprise saponins, naturally occurring, synthetic or semisynthetic saponin molecules; e.g. saponins and saponin fractions from Quil A, cell wall skeleton, block polymers, TDM, lipopeptides, LPS and LPS-derivatives, Lipid A from different bacterial species and derivatives thereof, e.g., monophosphoryl lipid A, CpG variants, CT and LT or fractions thereof.Type: ApplicationFiled: January 18, 2018Publication date: December 27, 2018Applicant: NOVAVAX ABInventors: Bror Morein, Karin Lövgren Bengtsson, Jill Ekström, Katarina Ranlund, Kefei Hu
-
Publication number: 20160184427Abstract: Fraction A of Quil A can be used together with at least one other adjuvant for the preparation of an adjuvant composition, where the included adjuvant components act synergistically to enhance level of immune response and have synergistic immunomodulating activity on the co-administered antigens or immunogens. Other adjuvants can comprise saponins, naturally occurring, synthetic or semisynthetic saponin molecules; e.g. saponins and saponin fractions from Quil A, cell wall skeleton, block polymers, TDM, lipopeptides, LPS and LPS-derivatives, Lipid A from different bacterial species and derivatives thereof, e.g., monophosphoryl lipid A, CpG variants, CT and LT or fractions thereof.Type: ApplicationFiled: February 26, 2016Publication date: June 30, 2016Inventors: Bror Morein, Karin Lövgren Bengtsson, Jill Ekström, Katarina Ranlund, Kefei Hu
-
Patent number: 9205147Abstract: Iscom particles can be used as an adjuvant for preparing of an antigenic composition which comprises live micro-organisms and/or killed micro-organisms and/or antigenic molecules. A composition may comprise at least one iscom particle and one or more live micro-organisms and/or killed micro-organisms and/or antigenic molecules. A kit can comprise at least one compartment containing at least one living organism and at least one compartment containing at least one iscom particle.Type: GrantFiled: January 2, 2014Date of Patent: December 8, 2015Assignee: Novavax ABInventors: Bror Morein, Karin Lövgren Bengtsson
-
Publication number: 20150320858Abstract: Fraction A of Quil A can be used together with at least one other adjuvant for the preparation of an adjuvant composition, where the included adjuvant components act synergistically to enhance level of immune response and have synergistic immunomodulating activity on the co-administered antigens or immunogens. Other adjuvants can comprise saponins, naturally occurring, synthetic or semisynthetic saponin molecules; e.g. saponins and saponin fractions from Quil A, cell wall skeleton, block polymers, TDM, lipopeptides, LPS and LPS-derivatives, Lipid A from different bacterial species and derivatives thereof, e.g., monophosphoryl lipid A, CpG variants, CT and LT or fractions thereof.Type: ApplicationFiled: May 18, 2015Publication date: November 12, 2015Inventors: Bror Morein, Karin Lövgren Bengtsson, Jill Ekström, Katarina Ranlund, Kefei Hu
-
Publication number: 20150209425Abstract: The invention relates to a composition comprising a mixture of at least two iscom complexes each complex comprising essentially one saponin fraction from Quillaja Saponaria Molina. The complexes may be iscom complexes or iscom matrix complexes. The invention also pertains to the use of such a mixture for the preparation of an immunomodulating pharmaceutical, and adjuvant, formulations for immunization, e.g. for production of monoclonal antibodies, and a vaccine. Kits of parts comprising at least two parts, wherein each part comprises one iscom complex or one iscom matrix complex according to the invention are also embraced.Type: ApplicationFiled: December 31, 2014Publication date: July 30, 2015Inventors: BROR MOREIN, KARIN LÖVGREN BENGTSSON
-
Publication number: 20140335049Abstract: Fraction A of Quil A can be used together with at least one other adjuvant for the preparation of an adjuvant composition, where the included adjuvant components act synergistically to enhance level of immune response and have synergistic immunomodulating activity on the co-administered antigens or immunogens. Other adjuvants can comprise saponins, naturally occurring, synthetic or semisynthetic saponin molecules; e.g. saponins and saponin fractions from Quil A, cell wall skeleton, block polymers, TDM, lipopeptides, LPS and LPS-derivatives, Lipid A from different bacterial species and derivatives thereof, e.g., monophosphoryl lipid A, CpG variants, CT and LT or fractions thereof.Type: ApplicationFiled: July 29, 2014Publication date: November 13, 2014Inventors: Bror Morein, Karin Lövgren Bengtsson, Jill Ekström, Katarina Ranlund, Kefei Hu
-
Publication number: 20140120131Abstract: Iscom particles can be used as an adjuvant for preparing of an antigenic composition which comprises live micro-organisms and/or killed micro-organisms and/or antigenic molecules. A composition may comprise at least one iscom particle and one or more live micro-organisms and/or killed micro-organisms and/or antigenic molecules. A kit can comprise at least one compartment containing at least one living organism and at least one compartment containing at least one iscom particle.Type: ApplicationFiled: January 2, 2014Publication date: May 1, 2014Applicant: Novavax ABInventors: Bror Morein, Karin Lövgren Bengtsson
-
Patent number: 8187585Abstract: The present invention relates to a composition comprising at least one fibronectin binding protein, and/or at least one a truncated fibronectin binding protein and/or at least one fibronectin binding peptide, all comprising at least one fibronectin binding domain; and at least one iscom matrix complex and/or liposome and/or at least one lipid and at least one saponin, whereby the at least one lipid and the at least one saponin may be in complex, solution or suspension. Further, it regards use thereof for the preparation of a vaccine against a micro organism that comprises at least one fibronectin binding domain. It also relates to a kit of parts comprising at least two compartments, wherein one compartment comprises at least one truncated fibronectin binding protein and/or a fibronectin binding peptide, that comprises at least one fibronectin binding domain, and another compartment comprises an instruction for use and/or an iscom matrix complex and/or an iscom complex and or a liposome.Type: GrantFiled: July 20, 2011Date of Patent: May 29, 2012Assignee: Isconova ABInventors: Bror Morein, Karin Lövgren Bengtsson, Jill Ekstrom, Katarina Ranlund, Birgitta Fromgren, Carlos Concha Bascunan
-
Publication number: 20120107353Abstract: The invention relates to a composition comprising at least one ISCOM complex and at least one internal antigen which is not a surface antigen and not in the form of a part of a whole micro-organism. The internal antigen may be a nucleoprotein or presented as a member of the group of components obtained after disintegrating a micro-organism. The ISCOM complex may be an ISCOM or ISCOM matrix complex. The composition may also comprise non internal antigens. The invention also elates to the composition for use as an immune stimulating medicine or vaccine, especially for use in eliciting T cell respond including CTL respond. The invention also relate to a composition comprising at least one ISCOM complex for use as an immune stimulating or immune modulating medicine or vaccine for the stimulation of dendritic ceils in elderly.Type: ApplicationFiled: July 9, 2010Publication date: May 3, 2012Applicant: ISCONOVA ABInventors: Bror Morein, Karin Lövgren Bengtsson
-
Publication number: 20110303563Abstract: The present invention relates to a composition comprising at least one fibronectin binding protein, and/or at least one a truncated fibronectin binding protein and/or at least one fibronectin binding peptide, all comprising at least one fibronectin binding domain; and at least one iscom matrix complex and/or liposome and/or at least one lipid and at least one saponin, whereby the at least one lipid and the at least one saponin may be in complex, solution or suspension. Further, it regards use thereof for the preparation of a vaccine against a micro organism that comprises at least one fibronectin binding domain. It also relates to a kit of parts comprising at least two compartments, wherein one compartment comprises at least one truncated fibronectin binding protein and/or a fibronectin binding peptide, that comprises at least one fibronectin binding domain, and another compartment comprises an instruction for use and/or an iscom matrix complex and/or an iscom complex and or a liposome.Type: ApplicationFiled: July 20, 2011Publication date: December 15, 2011Applicant: Isconova ABInventors: Bror Morein, Karin Lövgren-Bengtsson, Katarina Ranlund, Birgitta Fromgren, Jill Ekstrom, Carlos Concha Bascunan
-
Patent number: 8007806Abstract: The present invention relates to a composition comprising at least one fibronectin binding protein, and/or at least one a truncated fibronectin binding protein and/or at least one fibronectin binding peptide, all comprising at least one fibronectin binding domain; and at least one Iscom matrix complex and/or liposome and/or at least one lipid and at least one saponin, whereby the at least one lipid and the at least one saponin may be in complex, solution or suspension. Further, it regards use thereof for the production of a vaccine against a micro organism that comprises at least one one fibronectin binding domain. It also regards a kit of parts comprising at least two compartments, wherein one compartment comprises at least one truncated fibronectin binding protein and/or a fibronectin binding peptide, that comprises at least one fibronectin binding domain, and another compartment comprises an instruction for use and/or an Iscom matrix complex and/or an iscom complex and or a liposome.Type: GrantFiled: January 20, 2006Date of Patent: August 30, 2011Assignee: Isconova ABInventors: Bror Morein, Karin Lövgren-Bengtsson, Katarina Ranlund, Birgitta Fromgren, Jill Ekstrom, Carlos Concha Baschunan